← Leaderboards
Leila Gobejishvili
Endoprotech, Inc.
$4,116,827
Attributed
$5,198,574
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $934.4K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,198,574 · 5
By mechanism
R01$2,248,119 · 1
R44$1,414,341 · 1
P20$870,002 · 1
R21$388,405 · 1
R43$277,707 · 1
Top collaborators
- Philip Bauer3 shared
- Claudio Maldonado2 shared
Others in their field
Top investigators on “Fda Approved”
- Thomas Macvittie · University Of Maryland Baltimore$64,108,499
- David H Walker · University Of Texas Medical Br Galveston$61,066,312
- Polly Chang · Sri International$60,528,575
- Henry F Chambers · Duke University$48,458,380
- Robert H Vonderheide · University Of Pennsylvania$48,412,540
- Susan Abushakra · Alzheon, Inc.$47,690,244
Research focus
Fda ApprovedCyclic AmpHepatocyteIn VivoPlayLiver InjuryIn VitroMediatingInjuryPhosphodiesterase IvPde4bAttenuatedRegulationEnzymesCyclic Amp-Dependent Protein KinasesAlcoholic Liver DiseasesGenesLiverHepaticPhosphorylationAlcoholsLiver DiseasesSecond Messenger SystemsKnockout Mice
Grant awards (19)
Phosphodiesterase 4 mediated pathogenic mechanisms in alcohol associated liver disease$353,403
R01 · FY2025 · AA · contact PI
Phosphodiesterase 4 mediated pathogenic mechanisms in alcohol associated liver disease$104,281
R01 · FY2025 · AA · contact PI
Phosphodiesterase 4 mediated pathogenic mechanisms in alcohol associated liver disease$353,403
R01 · FY2024 · AA · contact PI
Phosphodiesterase 4 mediated pathogenic mechanisms in alcohol associated liver disease$156,422
R01 · FY2024 · AA · contact PI
Phosphodiesterase 4 mediated pathogenic mechanisms in alcohol associated liver disease$353,403
R01 · FY2023 · AA · contact PI
Phosphodiesterase 4 mediated pathogenic mechanisms in alcohol associated liver disease$156,422
R01 · FY2023 · AA · contact PI
Phosphodiesterase 4 mediated pathogenic mechanisms in alcohol associated liver disease$52,138
R01 · FY2023 · AA · contact PI
Phosphodiesterase 4 mediated pathogenic mechanisms in alcohol associated liver disease$355,125
R01 · FY2022 · AA · contact PI
Phosphodiesterase 4 mediated pathogenic mechanisms in alcohol associated liver disease$363,522
R01 · FY2021 · AA · contact PI
Pathogenic role of PDE4 in hepatic stellate cell activation and TGF signaling$170,759
P20 · FY2020 · GM · contact PI
Pathogenic role of PDE4 in hepatic stellate cell activation and TGF signaling$174,430
P20 · FY2019 · GM · contact PI
Pathogenic role of PDE4 in hepatic stellate cell activation and TGF signaling$151,508
P20 · FY2018 · GM · contact PI
Pathogenic role of PDE4 in hepatic stellate cell activation and TGF signaling$188,625
P20 · FY2017 · GM · contact PI
Novel Drug Carrier System for the Treatment of Alcoholic Liver Disease$749,725
R44 · FY2016 · AA
Pathogenic role of PDE4 in hepatic stellate cell activation and TGF signaling$184,680
P20 · FY2016 · GM · contact PI
Novel Drug Carrier System for the Treatment of Alcoholic Liver Disease$664,616
R44 · FY2015 · AA
The role of hepatocyte cAMP/PDE4 in alcohol-induced liver steatosis and injury$172,780
R21 · FY2015 · AA · contact PI
The role of hepatocyte cAMP/PDE4 in alcohol-induced liver steatosis and injury$215,625
R21 · FY2014 · AA · contact PI
Device for Delivery of Rolipram to Liver for Treatment of Alcoholic Liver Disease$277,707
R43 · FY2012 · AA